Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer

BACKGROUND: Resistance to tamoxifen (TAM) frequently occurs in the treatment of estrogen receptor positive (ER+) breast cancer. Accumulating evidences indicate that transcription factor HOXB13 is of great significance in TAM resistance. However, the regulation of HOXB13 in TAM-resistant breast cance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Liu, Bowen, Wang, Tianjiao, Wang, Huawei, Zhang, Lu, Xu, Feifei, Fang, Runping, Li, Leilei, Cai, Xiaoli, Wu, Yue, Zhang, Weiying, Ye, Lihong
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5824486/
https://ncbi.nlm.nih.gov/pubmed/29471853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0577-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados